20 years ago, Teva, the world's largest generics drug company, developed a proprietary drug, which turned out to be a bonanza: Copaxone for the treatment of multiple sclerosis. Copaxone sales set new records every year, but the party is apparently about to end. From May 2014, Teva will likely face competition from generic Copaxone as well from the expected launch in the coming years of improved brand drugs by competitors. This follows the launch a few months ago of oral multiple sclerosis drug Tecfidera, made by Biogen Idec Inc. (Nasdaq: BIIB), Teva's longstanding rival and the first company with a multiple sclerosis drug.
Click here to read more
